Soteria Biotech Co., Ltd.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Our services offer specialized, customized fluid dynamics and cloud computations. The software is based on patented proprietary algorithm that is easy to use, especially suitable for researchers or anyone in a time-constrained environment.
Founded Year
2016
Unified Business No.
43859045
Status
Active
Number of Employees
0
Total Paid-in
Capital
37,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Soteria Biotech Co., Ltd. is a Taiwan-based company that develops innovative medical software. It develops patents and sells products for respiratory diseases. Our first product “Soteria One Point Zero” is a medical cloud software designed to assist in the diagnosis and treatment of Obstructive Sleep Apnea Syndrome (OSAS). The development of this product originated from the CEO Honda Hsiao’s ten-year research in the sleep medicine field at the National Center for High-performance Computing. During the research period, he worked together with the Sleep Center of Chang Gung Memorial Hospital and the Sleep Center of China Medical University and successfully published results. Established Soteria Biotech Co., Ltd., and actively developed more advanced and better products. Currently, it has obtained patients in Taiwan, the United States and Singapore. The main target customers are patients with OSAS and patients waiting in line for diagnosis, to provide better solutions.
